Predicine to Present 10 Liquid Biopsy Studies at ASCO 2024
HAYWARD, Calif., May 21, 2024 (GLOBE NEWSWIRE) — Predicine, Inc. A leading precision oncology company, announced today that it will present data from 10 ctDNA studies at ASCO 2024, spotlighting the clinical utility of Predicine’s genomic and epigenomic liquid biopsy solutions for patient selection, disease monitoring, and drug resistance mechanism studies.
The forthcoming data represents significant potential for the practical application of Predicine’s cutting-edge liquid biopsy technology in personalized cancer care, clinical trials, and Companion Diagnostic (CDx) development.
Numerous studies to be unveiled at the conference emphasize the distinct advantages of personalized PredicineBEACON™ and methylation-based PredicineALERT™ MRD underscoring the clinical utility of Predicine’s liquid biopsy portfolio in biomarker discovery, therapy selection, MRD monitoring, and drug resistance mechanism analyses.
About Predicine
Predicine is a leading molecular insights company committed to advancing precision medicine in oncology. Predicine has developed a proprietary cell-free DNA and cell-free RNA-based liquid biopsy technology enabling minimally invasive molecular diagnosis for treatment selection, therapy monitoring, and minimal residual disease and early cancer detection. The Predicine portfolio comprises state-of-the-art blood, urine, and tissue-based Next-Generation Sequencing (NGS) assays designed for harmonized global use in research, clinical development, companion diagnostic (CDx) development, and patient testing. With operational hubs in Silicon Valley, Houston, Chicago, and Shanghai, Predicine collaborates with leading biopharma companies, institutions, and governments in personalized healthcare on a global scale. For more information, please visit us on http://www.predicine.com and follow us on LinkedIn or Twitter (X).
Contact Information:
Predicine, Inc.
media@predicine.com